JPWO2020150375A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020150375A5
JPWO2020150375A5 JP2021541022A JP2021541022A JPWO2020150375A5 JP WO2020150375 A5 JPWO2020150375 A5 JP WO2020150375A5 JP 2021541022 A JP2021541022 A JP 2021541022A JP 2021541022 A JP2021541022 A JP 2021541022A JP WO2020150375 A5 JPWO2020150375 A5 JP WO2020150375A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541022A
Other versions
JP2022517267A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013722 external-priority patent/WO2020150375A1/en
Publication of JP2022517267A publication Critical patent/JP2022517267A/ja
Publication of JPWO2020150375A5 publication Critical patent/JPWO2020150375A5/ja
Pending legal-status Critical Current

Links

JP2021541022A 2019-01-16 2020-01-15 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター Pending JP2022517267A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962793058P 2019-01-16 2019-01-16
US62/793,058 2019-01-16
PCT/US2020/013722 WO2020150375A1 (en) 2019-01-16 2020-01-15 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Publications (2)

Publication Number Publication Date
JP2022517267A JP2022517267A (ja) 2022-03-07
JPWO2020150375A5 true JPWO2020150375A5 (ja) 2022-12-13

Family

ID=69593774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541022A Pending JP2022517267A (ja) 2019-01-16 2020-01-15 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター

Country Status (19)

Country Link
US (2) US11707536B2 (ja)
EP (1) EP3911672A1 (ja)
JP (1) JP2022517267A (ja)
KR (1) KR20210117291A (ja)
CN (1) CN113614104A (ja)
AR (1) AR117825A1 (ja)
AU (1) AU2020208375A1 (ja)
BR (1) BR112021013874A2 (ja)
CA (1) CA3127065A1 (ja)
CL (1) CL2021001880A1 (ja)
CO (1) CO2021009338A2 (ja)
EA (1) EA202191977A1 (ja)
EC (1) ECSP21060605A (ja)
IL (1) IL284648A (ja)
MX (1) MX2021008550A (ja)
PE (1) PE20220429A1 (ja)
SG (1) SG11202107421YA (ja)
TW (1) TW202039546A (ja)
WO (1) WO2020150375A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
WO2022211791A1 (en) * 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof
TW202400796A (zh) * 2022-03-11 2024-01-01 美商同源醫藥公司 雙向雙重啟動子表現載體及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
EP1572889B1 (en) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EP1453547B1 (en) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
KR100959454B1 (ko) 2007-12-10 2010-05-25 주식회사 동부하이텍 반도체 소자 및 그 제조 방법
JP5797551B2 (ja) 2008-04-22 2015-10-21 フエー・イー・ベー・フエー・ゼツト・ウエー 肝特異的核酸調節要素ならびにその方法および用途
US20120093840A1 (en) 2009-04-06 2012-04-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
KR102212098B1 (ko) 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
SG11201404885RA (en) 2012-02-15 2014-09-26 Amunix Operating Inc Factor viii compositions and methods of making and using same
WO2013123503A1 (en) 2012-02-17 2013-08-22 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
US10398787B2 (en) 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
AU2013336601B2 (en) 2012-10-26 2018-01-25 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
CN105209487A (zh) 2013-03-15 2015-12-30 拜耳医药保健有限公司 重组因子viii制剂
JP6735672B2 (ja) 2013-09-12 2020-08-05 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第ｖｉｉｉ因子ベクター
WO2016025764A2 (en) 2014-08-13 2016-02-18 The Children's Hospital Of Philadelphia An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
EP3253786A4 (en) 2015-02-06 2018-10-17 The University of North Carolina at Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
DK3270944T3 (da) 2015-03-17 2020-01-27 Univ Brussel Vrije Optimerede leverspecifikke ekspressionssystemer til FVIII og FIX
TW202302627A (zh) 2015-11-13 2023-01-16 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
CN112912112A (zh) * 2018-10-26 2021-06-04 Vrije布鲁塞尔大学 肝特异性核酸调节元件以及其方法及用途

Similar Documents

Publication Publication Date Title
JPWO2020150375A5 (ja)
BR102023005164A2 (ja)
BR102023001987A2 (ja)
BR102023001877A2 (ja)
BR202022009269U2 (ja)
BR202022005961U2 (ja)
BR202022001779U2 (ja)
BY13162U (ja)
BY13158U (ja)
CN307050431S (ja)
BY13137U (ja)
BY13136U (ja)
CN307083046S (ja)
CN307049010S (ja)
CN307090035S (ja)
BY13135U (ja)
CN307093655S (ja)
CN307045113S (ja)
BY13167U (ja)
BY13166U (ja)
CN307093689S (ja)
BY13165U (ja)
BY13164U (ja)
BY13163U (ja)
BY13149U (ja)